Updates in Cardiovascular Medicine: Diagnosis, Treatment and Technical Aspects: 2nd Edition

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Physiology and Pathology".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 874

Special Issue Editors


E-Mail Website
Guest Editor
Department of Cardiology, University Hospital of Patras, 26504 Rion-Patras, Greece
Interests: coronary artery disease; platelets; anticoagulation therapy; acute coronary syndromes; radial access for coronary interventions-snuffbox access; primary prevention
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Department of Cardiology, University Hospital of Patras, 26504 Rion-Patras, Greece
2. First Department of Cardiology, Hippocration General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece
Interests: coronary artery disease; percutaneous coronary interventions; intravascular imaging; acute coronary syndromes; antiplatelets; structural heart diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The first edition of this Special Issue was a great success (https://www.mdpi.com/journal/life/special_issues/O56B7LF2BW). Now, we invite you to be published in the second edition.

Cardiovascular science is developing rapidly; new diagnostic approaches, novel pharmaceutical treatments, and current interventional procedures have emerged in recent years. Our aim in this Special Issue is to cover all of the recent advances in cardiovascular medicine, including diagnostic, interventional, and technical aspects. We welcome all types of articles from all areas of cardiovascular medicine. Please feel free to contact us for further information regarding submission.

Dr. Grigorios Tsigkas
Dr. Anastasios Apostolos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiology
  • cardiovascular medicine
  • interventional cardiology

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

14 pages, 654 KiB  
Review
Gut Microbiome and Its Role in Valvular Heart Disease: Not a “Gutted” Relationship
by Gyanaranjan Nayak, Kyriakos Dimitriadis, Nikolaos Pyrpyris, Magdalini Manti, Nikolaos Kamperidis, Vasileios Kamperidis, Antonios Ziakas and Konstantinos Tsioufis
Life 2024, 14(4), 527; https://doi.org/10.3390/life14040527 - 19 Apr 2024
Viewed by 687
Abstract
The role of the gut microbiome (GM) and oral microbiome (OM) in cardiovascular disease (CVD) has been increasingly being understood in recent years. It is well known that GM is a risk factor for various CVD phenotypes, including hypertension, dyslipidemia, heart failure and [...] Read more.
The role of the gut microbiome (GM) and oral microbiome (OM) in cardiovascular disease (CVD) has been increasingly being understood in recent years. It is well known that GM is a risk factor for various CVD phenotypes, including hypertension, dyslipidemia, heart failure and atrial fibrillation. However, its role in valvular heart disease (VHD) is less well understood. Research shows that, direct, microbe-mediated and indirect, metabolite-mediated damage as a result of gut dysbiosis and environmental factors results in a subclinical, chronic, systemic inflammatory state, which promotes inflammatory cell infiltration in heart valves and subsequently, via pro-inflammatory molecules, initiates a cascade of reaction, resulting in valve calcification, fibrosis and dysfunction. This relationship between GM and VHD adds a pathophysiological link to the pathogenesis of VHD, which can be aimed therapeutically, in order to prevent or regress any risk for valvular pathologies. Therapeutic interventions include dietary modifications and lifestyle interventions, in order to influence environmental factors that can promote gut dysbiosis. Furthermore, the combination of probiotics and prebiotics, as well as fecal m transplantation and targeted treatment with inducers or inhibitors of microbial enzymes have showed promising results in animal and/or clinical studies, with the potential to reduce the inflammatory state and restore the normal gut flora in patients. This review, thus, is going to discuss the pathophysiological links behind the relationship of GM, CVD and VHD, as well as explore the recent data regarding the effect of GM-altering treatment in CVD, cardiac function and systemic inflammation. Full article
Show Figures

Figure 1

Back to TopTop